日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypes

针对乳腺癌亚型的肿瘤免疫微环境的多平台分析

Torland, Lilly Anne; Geisler, Jürgen; Azimzade, Youness; Frafjord, Astri; Røed Nilsen, Hogne; Buer, Linn; Lømo, Jon; Garred, Øystein; Tahiri, Andliena; Lyngra, Marianne; Øynebråten, Inger; Corthay, Alexandre; Sahlberg, Kristine; Kristensen, Vessela; Tekpli, Xavier

Benign breast tumors may arise on different immunological backgrounds

良性乳腺肿瘤可能在不同的免疫学背景下发生。

Torland, Lilly Anne; Lai, Xiaoran; Kumar, Surendra; Riis, Margit H; Geisler, Jürgen; Lüders, Torben; Tekpli, Xavier; Kristensen, Vessela; Sahlberg, Kristine; Tahiri, Andliena

The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer

NEOLETRIB试验:来曲唑和瑞博西尼新辅助治疗ER阳性、HER2阴性乳腺癌

Fjermeros, Kamilla; Ghannoum, Salim; Geisler, Stephanie B; Bhargava, Sameer; Tahiri, Andliena; Klajic, Jovana; Lüders, Torben; Fongård, Marie; Nawaz, Meh Sameen; Bosnjak-Olsen, Tatjana; Buvarp, Unn-Cathrin Edvardsen; Rosenskiold, Aino Katri Johanna; Nguyen, Nam Thi; Sletbak, Tone Tysko; Seyedzadeh, Manouchehr; Selsås, Knut; Porojnicu, Alina Carmen; Skjerven, Helle Kristine; Hovda, Tone; Sahlberg, Kristine Kleivi; Torland, Lilly Anne; Lyngra, Marianne; Hammarström, Clara Louise; Hönigsperger, Elma Bahonjic; Noone, John Christopher; Mathiassen, Silje; Hurtado, Antoni; Goel, Shom; Koff, Andrew; Tekpli, Xavier; Kristensen, Vessela N; Geisler, Jürgen

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer

体外高通量筛选发现达沙替尼可作为乳腺癌HER2靶向药物联合治疗的候选药物

Normann, Lisa Svartdal; Haugen, Mads Haugland; Hongisto, Vesa; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Kristensen, Vessela N; Tahiri, Andliena; Engebraaten, Olav; Sahlberg, Kristine Kleivi; Mælandsmo, Gunhild Mari

Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors

肾细胞癌、良性肾组织中的激酶活性分析以及对四种不同酪氨酸激酶抑制剂的反应

Andliena Tahiri, Katarina Puco, Faris Naji, Vessela N Kristensen, Glenny Cecilie Alfsen, Lorant Farkas, Frode S Nilsen, Stig Müller, Jan Oldenburg, Jürgen Geisler

Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin

乳腺癌患者中非甾体类和甾体类芳香化酶抑制剂之间缺乏交叉耐药性:脂肪因子瘦素的潜在作用

Bahrami, Nazli; Jabeen, Shakila; Tahiri, Andliena; Sauer, Torill; Ødegård, Hilde Presterud; Geisler, Stephanie Beate; Gravdehaug, Berit; Reitsma, Laurens Cornelus; Selsås, Knut; Kristensen, Vessela; Geisler, Jürgen

Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer

孕激素受体缺失与乳腺癌中不同的酪氨酸激酶谱相关

Tahiri, Andliena; Tekpli, Xavier; Satheesh, Somisetty V; DeWijn, Rik; Lüders, Torben; Bukholm, Ida R; Hurtado, Antoni; Geisler, Jürgen; Kristensen, Vessela N

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer

miRNA551b-3p激活抑癌素信号模块,促进三阴性乳腺癌的进展

Deepak Parashar ,Anjali Geethadevi ,Miriam Ragle Aure ,Jyotsna Mishra ,Jasmine George ,Changliang Chen ,Manoj K Mishra ,Andliena Tahiri ,Wei Zhao ,Bindu Nair ,Yiling Lu ,Lingegowda S Mangala ,Cristian Rodriguez-Aguayo ,Gabriel Lopez-Berestein ,Amadou K S Camara ,Mingyu Liang ,Janet S Rader ,Ramani Ramchandran ,Ming You ,Anil K Sood ,Vessela N Kristensen ,Gordon B Mills ,Sunila Pradeep ,Pradeep Chaluvally-Raghavan

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma

维莫非尼对BRAF(V600E)和BRAF野生型转移性恶性黑色素瘤的体外肿瘤激酶活性具有差异性抑制作用

Tahiri, Andliena; Røe, Kathrine; Ree, Anne H; de Wijn, Rik; Risberg, Karianne; Busch, Christian; Lønning, Per E; Kristensen, Vessela; Geisler, Jürgen